Global /Canada /Healthcare /Biotechnology /METX

ME Therapeutics Holdings Inc.

METX

• CSE: METX • Delayed

2.50CAD 0%

1.76 USD

As of 24 June 2026, ME Therapeutics Holdings Inc. has a market cap of $52.85M USD, ranking #30183 globally and #929 in Canada. It ranks #2734 in the Healthcare sector, and #527 in the Biotechnology industry.

Global Rank

30183

Country Rank

929

Sector Rank

2734

Industry Rank

527

Key Stats

Market Cap

$52.85MUSD

75.12M CAD

Enterprise Value

$52.16MUSD

73.94M CAD

EBITDA (TTM)

-$1.02MUSD

-1.45M CAD

Net Income (TTM)

-$939.57KUSD

-1.34M CAD

PB Ratio

72.0

Company Profile

Country (HQ)

Canada

Sector

Healthcare

Industry

Biotechnology

CEO

Salim Dhanji open_in_new

Founded

2014

Website

metherapeutics.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	-16%	-17%	-38%	-38%	-38%	-69%	4K%	4K%

News

Markets

Exchange	Ticker	Price	Quotes
Canadian Securities Exchange (CSE) MIC: XCNQ PRIMARY	METX ME Therapeutics Holding Inc ISIN: CA5527671054 Shares Out.: Shares Outstanding: 30.049M¹ Shares Float: 13.518M² TV: TradingView: CSE: METX SA: Stock Analysis: CSE: METX YF: Yahoo Finance: METX.CN GF: Google Finance: CNSX: METX BA: Barron's: METX MS: Morningstar: XCNQ: METX	2.50 CAD	TV: TradingView: CSE: METX SA: Stock Analysis: CSE: METX YF: Yahoo Finance: METX.CN GF: Google Finance: CNSX: METX BA: Barron's: METX MS: Morningstar: XCNQ: METX
Cboe Canada (NEO) MIC: NEOE	METX ME Therapeutics Holding Inc ISIN: CA5527671054 Shares Out.: Shares Outstanding: 29.589M¹ Shares Float: 10.46M² TV: TradingView: NEO: METX SA: Stock Analysis: NEO: METX YF: Yahoo Finance: METX.NE GF: Google Finance: NEO: METX BA: Barron's: METX MS: Morningstar: NEOE: METX	7.00 CAD	TV: TradingView: NEO: METX SA: Stock Analysis: NEO: METX YF: Yahoo Finance: METX.NE GF: Google Finance: NEO: METX BA: Barron's: METX MS: Morningstar: NEOE: METX

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About ME Therapeutics Holdings Inc.

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company’s lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics Holdings Inc. was founded in 2014 and is headquartered in Vancouver, Canada.

Similar Companies

Industry: Biotechnology (Canada)

Name	Market Cap (USD) diff.	PE	Country
Aurinia Pharmaceuticals Inc. NASDAQ: AUPH	$1.99B 4K%	7.4	Canada
AbCellera Biologics Inc. NASDAQ: ABCL	$1.16B 2K%	-	Canada
Eupraxia Pharmaceuticals Inc. TSX: EPRX	$422.74M 600.89M CAD 700%	-	Canada
NervGen Pharma Corp. TSXV: NGEN	$288.58M 410.19M CAD 446%	-	Canada
Cybin Inc. NEO: CYBN	$248.44M 353.13M CAD 370%	-	Canada
Cardiol Therapeutics Inc. TSX: CRDL	$146.39M 208.08M CAD 177%	-	Canada

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 345K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 302K%	19.0	United States
argenx SE EBR: ARGX	$47.29B 41.39B EUR 89K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.45B 68.19T KRW 84K%	35.5	South Korea
Lonza Group AG SIX: LONN	$41.67B 33.71B CHF 79K%	37.2	Switzerland
CSL Ltd. ASX: CSL	$41.65B 60.27B AUD 79K%	29.3	Australia

chevron_leftBack